AVAX is trading at $8.59, up 4.04% over 24 hours, showing a clear short-term rebound. The overall picture remains mixed: the daily move and hourly indicators are constructive, but performance over the past week, two weeks, and month is negative.

The price is near the 24-hour high of $8.72 and above the low of $8.27, a range of $0.45. This places AVAX toward the upper part of its daily range, consistent with positive near-term momentum, though the supplied data does not establish whether the move will persist.

All five hourly moving averages are below or approximately at the current price: the 8- and 13-hour averages are $8.58, the 21-hour average is $8.52, the 55-hour average is $8.51, and the 144-hour average is $8.33. Their reported positive differences, from 0.11% to 3.18%, reinforce the short-term bullish reading, with the price also above the longer hourly averages.

The 1-hour RSI of 58 indicates positive but not especially strong momentum, while the 7-day RSI of 53 is close to neutral and offers limited confirmation of a broad recovery. These readings do not contradict the recent price gain, but they temper it: neither RSI indicates exceptionally strong buying pressure in the supplied data.

The broader price record is weaker: AVAX is down 2.51% over seven days, 3.68% over 14 days, and 16.85% over 30 days. The larger monthly loss outweighs the modest weekly declines as evidence of the prevailing trend, so the daily rebound has not yet reversed the negative medium-term performance.

Volume is $237.3 million over 24 hours, with volume-to-market-cap at 6.19%; these figures provide activity context but, without comparison data, do not establish an unusual surge or confirm the move. At $8.59, AVAX is also about 94.1% below its $144.96 all-time high, a historical reference that underscores the scale of the longer-term decline but does not by itself predict near-term direction.

The rating is Hold. The strongest positive evidence is the 24-hour rise, price near the daily high, and position above the hourly moving averages; the strongest counterevidence is the negative seven-, 14-, and 30-day performance, especially the 30-day decline. With RSI readings only mildly positive and no supplied evidence that the broader downtrend has turned, the rebound is insufficient to support a Buy, while the improving short-term signals make a Sell less compelling.